Arthur Weinstein1,2,3, Roberta V Alexander4, Debra J Zack4. 1. Loma Linda University, Loma Linda, CA, USA. aw89@georgetown.edu. 2. Georgetown University, Washington, DC, USA. aw89@georgetown.edu. 3. Exagen Inc., Vista, CA, USA. aw89@georgetown.edu. 4. Exagen Inc., Vista, CA, USA.
Abstract
PURPOSE OF REVIEW: Complement activation is a key event in the pathogenesis of tissue inflammation and injury in systemic lupus erythematosus (SLE). This review is aimed at comparing the usefulness of measurement of complement proteins in serum/plasma (C3, C4) to complement activation (split) products in plasma and on circulating blood cells for SLE diagnosis, disease monitoring, and prognosis. RECENT FINDINGS: Complement split products, C3dg, iC3b, and C4d, are elevated in SLE, and C3dg/C3 and iC3b/C3 ratios correlate with active SLE. C4d also is higher in patients with lupus nephritis. An elevated level of the alternative pathway split product, Bb, in early lupus pregnancy is a predictor of adverse outcomes in SLE patients with antiphospholipid antibodies. Elevated levels of cell-bound complement activation products (CB-CAPs), namely, B cell-bound C4d (BC4d) and erythrocyte-bound C4d (EC4d), within a multiparameter assay panel, may predict transition to SLE more than other lupus biomarkers. EC4d better correlates with lupus disease activity than low plasma complement levels. Elevated platelet-bound C4d (PC4d) correlates with thrombosis in SLE. Both EC4d and PC4d are increased in primary and secondary anti-phospholipid syndrome, and anti-beta2glycoproteinI antibodies may directly activate the complement system. Abnormal levels of plasma complement split products and CB-CAPs support complement activation as an important pathogenetic mechanism in SLE and the antiphospholipid syndromes. These tests show promise for the diagnosis of SLE and monitoring of disease activity.
PURPOSE OF REVIEW: Complement activation is a key event in the pathogenesis of tissue inflammation and injury in systemic lupus erythematosus (SLE). This review is aimed at comparing the usefulness of measurement of complement proteins in serum/plasma (C3, C4) to complement activation (split) products in plasma and on circulating blood cells for SLE diagnosis, disease monitoring, and prognosis. RECENT FINDINGS: Complement split products, C3dg, iC3b, and C4d, are elevated in SLE, and C3dg/C3 and iC3b/C3 ratios correlate with active SLE. C4d also is higher in patients with lupus nephritis. An elevated level of the alternative pathway split product, Bb, in early lupus pregnancy is a predictor of adverse outcomes in SLEpatients with antiphospholipid antibodies. Elevated levels of cell-bound complement activation products (CB-CAPs), namely, B cell-bound C4d (BC4d) and erythrocyte-bound C4d (EC4d), within a multiparameter assay panel, may predict transition to SLE more than other lupus biomarkers. EC4d better correlates with lupus disease activity than low plasma complement levels. Elevated platelet-bound C4d (PC4d) correlates with thrombosis in SLE. Both EC4d and PC4d are increased in primary and secondary anti-phospholipid syndrome, and anti-beta2glycoproteinI antibodies may directly activate the complement system. Abnormal levels of plasma complement split products and CB-CAPs support complement activation as an important pathogenetic mechanism in SLE and the antiphospholipid syndromes. These tests show promise for the diagnosis of SLE and monitoring of disease activity.
Authors: J Nossent; E Kiss; B Rozman; G Pokorny; P Vlachoyiannopoulos; M Olesinska; A Marchesoni; M Mosca; S Påi; K Manger; M Schneider; H Nielsen; R van Vollenhoven; T Swaak Journal: Lupus Date: 2010-04-07 Impact factor: 2.911
Authors: G Moroni; A Radice; G Giammarresi; S Quaglini; B Gallelli; A Leoni; M Li Vecchi; M L Vecchi; P Messa; R A Sinico Journal: Ann Rheum Dis Date: 2008-08-21 Impact factor: 19.103
Authors: Odirlei André Monticielo; Tamara Mucenic; Ricardo Machado Xavier; João Carlos Tavares Brenol; José Artur Bogo Chies Journal: Clin Rheumatol Date: 2008-01-24 Impact factor: 2.980
Authors: Myriam Martin; Karolina I Smoląg; Albin Björk; Birgitta Gullstrand; Marcin Okrój; Jonatan Leffler; Andreas Jönsen; Anders A Bengtsson; Anna M Blom Journal: Arthritis Res Ther Date: 2017-12-06 Impact factor: 5.156
Authors: Rosalind Ramsey-Goldman; Roberta Vezza Alexander; Elena M Massarotti; Daniel J Wallace; Sonali Narain; Cristina Arriens; Christopher E Collins; Amit Saxena; Chaim Putterman; Kenneth C Kalunian; Tyler O'Malley; Thierry Dervieux; Arthur Weinstein Journal: Arthritis Rheumatol Date: 2019-11-25 Impact factor: 10.995
Authors: Alfred H J Kim; Vibeke Strand; Deepali P Sen; Qiang Fu; Nancy L Mathis; Martin J Schmidt; Robin R Bruchas; Nick R Staten; Paul K Olson; Chad M Stiening; John P Atkinson Journal: Arthritis Rheumatol Date: 2019-01-24 Impact factor: 10.995